Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,687.80down ₹72.00 (1.92%)BSE ₹3,687.05
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,759.80.
30 Oct: open ₹3,760.00, high ₹3,776.90, low ₹3,668.10
52-week range of traded prices to 30 Oct 2026
₹3,589.00Low, 23 Oct 2026₹5,346.00High, 30 Oct 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,871 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.95
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.01
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.03%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,12450.8% delivered
Pfizer board meetings
106 filed, newest first. Page 2 of 3.
May 2018
7 May · Board meeting
Apr 2018
Jan 2018
Oct 2017
Jul 2017
Apr 2017
Jan 2017
Oct 2016
Jul 2016
Apr 2016
Jan 2016
Oct 2015
Jul 2015
Apr 2015
Feb 2015
Jan 2015
28 Jan · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2014.
Oct 2014
21 Oct · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2014. Further Trading Window for trading in the Equity shares of the Company will be closed from October 22, 2014 to November 7, 2014, both days inclusive.
Jul 2014
14 Jul · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2014. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from July 15, 2014 to July 25, 2014, both days inclusive.
May 2014
5 May · Board meeting
Company paid an interim dividend of Rs. 360/- per share of Rs. 10/- each (3600%) aggregating to Rs. 1,07,429 Lakhs. The Board of Directors Company have not recommended any further Dividend for the financial year ended March 31, 2014.
Apr 2014
22 Apr · Board meeting
Inter alia, to consider and take on record the Audited Financial Results for the quarter January 1, 2014 to March 31, 2014 and for the year ended March 31, 2014. At the said meeting, the Board of Directors will also consider recommendation of final Dividend, if any, for the year ended March 31, 2014. The Trading Window for trading in the Equity shares of the Company is closed from April 23, 2014 to May 2, 2014, both days inclusive.
Jan 2014
21 Jan · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2013.
Nov 2013
20 Nov · Board meeting
Inter alia, to transact the following:(1) To consider a Scheme of Amalgamation of Wyeth Limited with the Company.(2) To consider declaration of Interim Dividend.
Jul 2013
16 Jul · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2013.
May 2013
8 May · Board meeting
Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 03, 2013 To consider and take on record the Audited Financial Results for the quarter, January 1, 2013 to March 31, 2013 and the year ended March 31, 2013 and to consider recommendation of Dividend, if any, for the year ended March 31, 2013 and also informed dated May 03, 2013 about the postponement of the said Board Meeting. The Company has now informed the Exchange that a meeting of the Board of Directors of the Company will be held on May 14, 2013, inter alia, to consider and take on record the Audited Financial Results for the quarter, January 01, 2013 to March 31, 2013 and the year ended March 31, 2013. At the said meeting, the Board of Directors will also consider recommendation of Dividend, if any, for the year ended March 31, 2013.Not held on this date
Apr 2013
Jan 2013
29 Jan · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2012.
Nov 2012
8 Nov · Board meeting
Board of Directors of the Company at its meeting held on November 08, 2012 has approved, subject to receipt of prior regulatory approvals, the sale of its wholly owned subsidiary Pfizer Animal Pharma Private Limited to Pfizer Animal Health India Limited, a 100% indirect subsidiary of Pfizer Inc., USA for a consideration of Rs. 471.60 Crores (Rupees Four Hundred and Seventy One Crores and Sixty Lakhs only).
Oct 2012
26 Oct · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2012.
Aug 2012
1 Aug · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2012.
Jun 2012
28 Jun · Board meeting
Board of Directors of the Company at their Meeting held on June 28, 2012 accepted the resignation of Mr. Kewal Handa as the Director and Managing Director of the Company with effect from the end of day on August 15, 2012. Mr. Kewal Handa would continue as an employee of the Company until his retirement from the Company i.e. August 31, 2012. Further, the Board of Directors of the Company at their Meeting held on June 28, 2012 appointed Mr. Aijaz Tobaccowalla as an Additional Director of the Company with immediate effect. Further, the Board of Directors of the Company at their Meeting held on June 28, 2012 also appointed Mr. Aijaz Tobaccowalla as the Managing Director of the Company with effect from August 16, 2012 subject to approval of shareholders and Central Government.
May 2012
10 May · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2012 and to recommend dividend thereon.
Jan 2012
19 Jan · Board meeting
Inter-alia to consider and approve the unaudited Financial Results of the Company for the 3rd quarter ended December 31, 2011.
Oct 2011
11 Oct · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results of the Company for the 2nd quarter ended September 30, 2011.
Jul 2011
22 Jul · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2011.
Apr 2011
21 Apr · Board meeting
Inter-alia to consider and approve the Audited Financial Results of the Company for the 16 months period December 01, 2009 to March 31, 2011 and to recommend final dividend, thereon, if any.
Dec 2010
29 Dec · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 4th Quarter ended November 30, 2010.
Sep 2010
27 Sep · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 3rd quarter ended August 31, 2010.
Jun 2010
29 Jun · Board meeting
To consider and approve the Un-audited Financial Results for the Second quarter ended May 31, 2010.
Mar 2010
19 Mar · Board meeting
Pfizer Ltd. has informed the Exchange regarding the outcome of Board meeting held today for the reconsideration of financial results on account of Court Approval to the Scheme of Amalgamation between Duchem Laboratories Limited (the unlisted wholly-owned subsidiary) with Pfizer Limited. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Board meeting
Interalia to consider and approve the Unaudited Financial Results for the 1st Quarter ended February 28, 2010.18 Mar · Board meeting
Company proposes to reconsider the audited Financial Results of the merged entity i.e. Pfizer Ltd. and Duchem Laboratories Ltd. A meeting of the Board of Directors of Pfizer Ltd. would be held on March 19, 2010, to reconsider and approve the Annual Financial Results of the merged entity with a view to give effect to the Court order.
Feb 2010
17 Feb · Board meeting
To consider the Audited Financial Results of the Company for the year ended November 30, 2009 and to recommend dividend thereon.
Sep 2009
17 Sep · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 3rd quarter ended August 31, 2009.
Jun 2009
19 Jun · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 2nd quarter ended May 31, 2009.
Mar 2009
19 Mar · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 1st quarter ended February 28, 2009.
Jan 2009
22 Jan · Board meeting
To consider the Audited Statement of Accounts of the Company for the year ended November 30, 2008 and to recommend dividend thereon.
Sep 2008
22 Sep · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 3rd quarter ended August 31, 2008.
Jun 2008
20 Jun · Board meeting
Inter-alia to consider the Unaudited Financial Results for the 2nd quarter ended May 31, 2008.